Jennison Associates
PRTK

Jennison Associates’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Jennison Associates’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-303,048
Closed -$5.76M – 743
2015
Q3 		$5.76M Buy
303,048
+1,534
+0.5% +$38.2K 0.01% 534
2015
Q2 		$7.77M Buy
+301,514
New +$8.56M 0.01% 527

Other funds holding PRTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates's PRTK Position: Q4 2015 in Review

Jennison Associates sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2015, closing a stake of 303,048 shares — an estimated $5.76M sold.

Jennison Associates first reported a position in PRTK in Q2 2015 and held it in 2 quarters. The position peaked at $7.77M in Q2 2015. 62 funds tracked by Wall St. Rank hold PRTK as of Q4 2015.

  • Jennison Associates reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
  • Jennison Associates sold 303,048 Paratek Pharmaceuticals, Inc. shares in Q4 2015, an estimated $5.76M.
  • Jennison Associates first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 2 quarters.
  • Jennison Associates's Paratek Pharmaceuticals, Inc. position peaked at $7.77M in Q2 2015.
  • 62 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2015.

Based on Jennison Associates's 13F filing for Q4 2015, filed 10 Feb 2016.